Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • COVIFENZ Plant based COVID-19 Vaccine approved by Health Canada

    Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline announced that Health Canada has granted approval for COVIFENZ, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age.

  • Glucophage the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy

    Merck, a leading science and technology company, today announced in a European worksharing procedure (WSP) an extension to the label for metformin products in the EU - Glucophage (metformin hydrochloride [HCL] immediate release), Glucophage XR (metformin HCL extended release) and Stagid® (metformin embonate immediate release) - for use throughout pregnancy.

  • CTI BioPharma announces FDA Accelerated Approval of VONJO

    CTI BioPharma Corp announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK. The recommended dosage of VONJO is 200 mg orally twice daily.

  • USFDA approves Carvykti First Cell Therapy of Janssen

    The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

  • Omalizumab provides benefit to patients with allergic asthma, regardless of BMI

    Researchers find out in a recent study that omalizumab provides benefit to patients with moderate to severe allergic asthma, regardless of body mass index.

  • Bharat Biotech to work on TB vaccine

    Bharat Biotech is in the process of bringing out a vaccine against tuberculosis and soon the firm will sign a MoU with another firm for technology.

    "Our honourable Prime Minister has got an agenda of 2025 for the eradication of tuberculosis. I think we are in that direction. But we don't have the technology so we are partnering with somebody else. On that matter we should be announcing soon," Krishna Ella, Chairman and Managing Director said in BioAsia 2022.

  • Online TABLT Pharmacy raised USD 1.5 million

    Kolkata-based TABLT Pharmacy has raised USD 1.5 million in pre-series A round from investors like JITO Angel Network, Tech Innovation, Lets Venture, Seeders Syndicate, Angel Bay and other angel investors. Also, the founders have themselves participated in this round.

    Tablt online pharmacy is launched in 2018 and it is dealing in medicines, OTCs and other healthcare products.

  • Repurposing FDA-approved drugs may help combat COVID-19

    Several FDA-approved drugs including for type 2 diabetes, hepatitis C and HIV significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Specifically, the team found that these drugs inhibit certain viral enzymes, called proteases, that are essential for SARS-CoV-2 replication in infected human cells.

  • Biocon Biologics to Acquire Viatris Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

    Biocon Biologics Ltd., a subsidiary of Biocon Ltd announced today that it has entered into a definitive agreement with its partner Viatris Inc.  . Accordingly, Biocon Biologics Ltd will acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive consideration of up to USD 3.335 billion, including cash up to USD 2.335 billion and Compulsorily Convertible Preference Shares  in BBL, valued at USD 1 billion.

  • Ministry of AYUSH collaborating with the Healthcare sector for Skill development said Vikram Singh, Director, Ministry of AYUSH

    PHD Chamber organized a technical session on Incentive and Schemes offered by Ministry of AYUSH, Govt. of India for ASU Sector on 24th February 2022 during AYUSH e-Mela.

Subscribe to Pharma News